399 related articles for article (PubMed ID: 27639381)
1. Regulation of antibody effector functions through IgG Fc N-glycosylation.
Quast I; Peschke B; Lünemann JD
Cell Mol Life Sci; 2017 Mar; 74(5):837-847. PubMed ID: 27639381
[TBL] [Abstract][Full Text] [Related]
2. Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies.
Le NP; Bowden TA; Struwe WB; Crispin M
Biochim Biophys Acta; 2016 Aug; 1860(8):1655-68. PubMed ID: 27105835
[TBL] [Abstract][Full Text] [Related]
3. A Method to Detect the Binding of Hyper-Glycosylated Fragment Crystallizable (Fc) Region of Human IgG1 to Glycan Receptors.
Blundell P; Pleass R
Methods Mol Biol; 2019; 1904():417-421. PubMed ID: 30539483
[TBL] [Abstract][Full Text] [Related]
4. Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases.
Trastoy B; Du JJ; García-Alija M; Li C; Klontz EH; Wang LX; Sundberg EJ; Guerin ME
Curr Opin Struct Biol; 2022 Feb; 72():248-259. PubMed ID: 34998123
[TBL] [Abstract][Full Text] [Related]
5. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.
Anthony RM; Ravetch JV
J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216
[TBL] [Abstract][Full Text] [Related]
6. Modulating IgG effector function by Fc glycan engineering.
Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
[TBL] [Abstract][Full Text] [Related]
7. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
8. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
9. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
10. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
11. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
12. Glycosylation of Antigen-Specific Antibodies: Perspectives on Immunoglobulin G Glycosylation in Vaccination and Immunotherapy.
Bharadwaj P; Ackerman ME
Exp Suppl; 2021; 112():565-587. PubMed ID: 34687023
[TBL] [Abstract][Full Text] [Related]
13. Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments.
Jez J; Antes B; Castilho A; Kainer M; Wiederkum S; Grass J; Rüker F; Woisetschläger M; Steinkellner H
J Biol Chem; 2012 Jul; 287(29):24313-9. PubMed ID: 22589538
[TBL] [Abstract][Full Text] [Related]
14. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
15. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
16. IgG N-glycans.
Liu S; Liu X
Adv Clin Chem; 2021; 105():1-47. PubMed ID: 34809825
[TBL] [Abstract][Full Text] [Related]
17. IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?
Kronimus Y; Dodel R; Galuska SP; Neumann S
J Autoimmun; 2019 Jan; 96():14-23. PubMed ID: 30360925
[TBL] [Abstract][Full Text] [Related]
18. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
19. Fc glycan-modulated immunoglobulin G effector functions.
Quast I; Lünemann JD
J Clin Immunol; 2014 Jul; 34 Suppl 1():S51-5. PubMed ID: 24760108
[TBL] [Abstract][Full Text] [Related]
20. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.
Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS
Front Immunol; 2017; 8():1554. PubMed ID: 29181010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
